The Royal Marsden Private Care

The Royal Marsden was the first hospital in the world dedicated to cancer when it opened in 1851, and together with its academic partner The Institute of Cancer Research (ICR), The Royal Marsden is one of the largest comprehensive cancer centres in Europe seeing and treating over 59,000 NHS and private cancer patients each year.

It is a centre of excellence with an international reputation for groundbreaking research, pioneering the latest cancer treatments and technologies, and world-leading cancer diagnosis and education.

The Royal Marsden and ICR undertake pioneering research with over 800 clinical studies undertaken at any time. Some of the treatments pioneered at The Royal Marsden and ICR include prostate cancer drug abiraterone, breast cancer drug herceptin and melanoma immunotherapy drugs ipiluminab and vemurafenib.

This research profile attracts world-class clinical staff to The Royal Marsden. Our 2,500 staff, including consultants, doctors and nurses, are all cancer experts.

This expertise is brought together in multidisciplinary team meetings, where every case is discussed by a team of surgeons, oncologists, nurses, radiologists and other experts to devise personalised treatment plans for each individual and ensure every Royal Marsden patient receives the best possible care.

Treatment facilities include nine state-of-the-art theatres with both the da Vinci S and da Vinci Xi robotic surgery systems, the UK’s largest cancer specific Level 3 Critical Care Unit, 11 linear accelerators, a brachytherapy suite, and a UK-first MR Linac. There are also extensive diagnostic, radiology, pathology and nuclear medicine services across both hospitals.

Education and support for staff is at the heart of The Royal Marsden’s success. The Royal Marsden Manual of Clinical Nursing Practice is the best-selling nursing textbook in the UK and The Royal Marsden School provides specialist training to over 700 nursing and allied health professionals each year.